Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 105/1 (Jan) pp. 1–205
Pages: 14-20

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

Online Supplementary Material

J. J. A. Auwerda (1), Y. Yuana (2), S. Osanto (2), M. P. M. de Maat (1), P. Sonneveld (1), R. M. Bertina (3), F. W. G. Leebeek (1)

(1) Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands; (2) Department of Clinical Oncology, Leiden University Medical Center, Leiden,; (3) Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands


Venous thrombosis, Multiple Myeloma, Tissue factor, microparticles


Multiple myeloma (MM) is associated with an increased risk of venous thromboembolic (VTE) complications. Aim of this study was to measure microparticle-associated tissue factor (MP-TF) activity in patients with newly diagnosed MM before and after chemotherapy and to investigate whether MP-TF activity is associated with VTE. MP-TF activity was assessed in 122 newly diagnosed MM patients who were eligible for combination chemotherapy. MP-TF activity levels (17.6 fM Xa/min [8.6–33.2] (median [IQR]) were higher in untreated MM patients compared to normal healthy volunteers (4.1 fM Xa/min [2.3–6.6], p <0.001). MP-TF activity prior to the start of treatment was not different between patients who developed a VTE during follow-up (n=15) and those who did not (n=107). In 75 patients in whom plasma was obtained before and after chemotherapy, MP-TF activity decreased significantly (from 17.4 [10.2–32.8] to 12.0 [7.0–18.5] fM Xa/min, P=0.006). MP-TF activity remained, however, elevated in patients who developed VTE (15.1 [10.3–25.2]), in contrast to patients not developing VTE (11.4 [7.0–25.2], P<0.001). In conclusion, MP-TF activity is increased in patients with MM. Whether MP-TF activity has a pathogenetic role in VTE in MM patients remains to be established in future studies.

You may also be interested in...

Eduardo Ramacciotti 1; Angela E. Hawley 1; Diana M. Farris 1; Nicole E. Ballard 1; Shirley K. Wrobleski 1; Daniel D. Myers Jr. 1,2; Peter K. Henke 1; Thomas W. Wakefield1

Thromb Haemost 2009 101 4: 748-754


Leigh A. Madden 1, Rebecca V. Vince 1, Marie E. Sandström 2, Lee Taylor 2, Lars McNaughton 2, Gerard Laden3

Thromb Haemost 2008 99 5: 909-915

Serena Del Turco 1,2, Giuseppina Basta 1, Guido Lazzerini 1, Monica Evangelista 1, Giuseppe Rainaldi 1, Piero Tanganelli 2, Marina Camera 3, Elena Tremoli 3, Raffaele De Caterina1,4

Thromb Haemost 2007 98 1: 210-219